Eli Lilly and Company (NYSE:LLY) Holdings Lessened by Saturna Capital Corp

Saturna Capital Corp reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 600,756 shares of the company’s stock after selling 28,326 shares during the quarter. Eli Lilly and Company makes up approximately 7.4% of Saturna Capital Corp’s investment portfolio, making the stock its largest position. Saturna Capital Corp owned approximately 0.06% of Eli Lilly and Company worth $496,170,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Prestige Wealth Management Group LLC grew its stake in shares of Eli Lilly and Company by 2.0% during the fourth quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company’s stock worth $468,000 after acquiring an additional 12 shares during the last quarter. Applied Finance Capital Management LLC raised its position in Eli Lilly and Company by 1.4% during the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock worth $660,000 after buying an additional 12 shares during the last quarter. Garner Asset Management Corp raised its holdings in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after purchasing an additional 12 shares during the last quarter. Tobias Financial Advisors Inc. boosted its holdings in Eli Lilly and Company by 4.1% in the fourth quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company’s stock valued at $237,000 after purchasing an additional 12 shares during the last quarter. Finally, Redwood Investments LLC raised its stake in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company’s stock valued at $1,705,000 after buying an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Morgan Stanley reiterated an “overweight” rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a “buy” rating in a report on Friday, July 11th. Finally, Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,012.56.

Eli Lilly and Company Price Performance

LLY stock opened at $762.04 on Friday. The stock’s 50 day moving average price is $766.32 and its 200 day moving average price is $799.83. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The firm has a market cap of $722.21 billion, a P/E ratio of 62.00, a PEG ratio of 1.15 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter last year, the firm earned $2.58 EPS. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.